ArticleWorld journal of urology2020
Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.
Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.World journal of urology · 2025Pooled it
- Prostatic stents: a systematic review and analysis of functional outcomes and complication rate.Prostate cancer and prostatic diseases · 2025Pooled it
- Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH.Prostate cancer and prostatic diseases · 2025Pooled it
- Impact of minimally invasive surgical procedures for Male Lower Urinary Tract Symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.World journal of urology · 2022Pooled it
- Functional outcomes and retreatment rates after iTIND implantation in a real-world Italian multicenter cohort: the importance of patient selection.International urology and nephrology · 2026Article
- Management of clinical failure after minimally invasive surgical therapies (MIST) for BPH: repeat MIST versus resection, enucleation or ablation-a narrative review from EAU endourology.World journal of urology · 2026Review
- State-of-the-art in minimally invasive treatments for benign prostatic obstruction.Investigative and clinical urology · 2026Review
- Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights.Research and reports in urology · 2025Review
- Minimally invasive surgical treatments for male lower urinary tract symptoms/benign prostatic enlargement: A review on sexual function outcomes.Bladder (San Francisco, Calif.) · 2025Review
- Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.Current urology reports · 2024Review
- Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?Asian journal of andrology · 2024Review
- Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia.European urology open science · 2022Article
- [Minimally invasive treatment options for the management of benign prostatic hyperplasia].Der Urologe. Ausg. A · 2021Article
- Do Minimally Invasive Benign Prostatic Hyperplasia Treatments Preserve Sexual Function? A Contemporary Review of the Literature.Current urology reports · 2021Review
- New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes.European urology open science · 2021Review
- iTIND for BPH: Technique and procedural outcomes: A narrative review of current literature.Turkish journal of urology · 2021Article
- Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm.World journal of urology · 2021Review
- Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review.BJUI compass · 2021Review
- 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction.Prostate cancer and prostatic diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAssessing medium-term functional results of a novel minimally-invasive treatment for lower urinary tract symptoms due to BPO with the second generation of the temporary implantable nitinol device (iTind; Medi-Tate Ltd
methodsFollowing local ethical committee approval in every participating centre, 81 men with symptomatic BPO (IPSS ≥ 10, peak urinary flow < 12 ml/s, and prostate volume < 75 ml) were enrolled in this study. Patients with PVR > 250 ml, obstructive median lobe, previous prostatic surgery, confounding bladder or sphincter dysfunction based on medical history, active urinary infection and unable to interrupt antithrombotic or antiplatelet treatment were exclusion criteria. A wash-out period of 1 month for alpha-blockers and 6 months for 5-ARIs was mandatory to avoid confounders. The procedure was performed as previously described: implantation under light sedation and removal 5-7 days later with topical sedation. Patients were assessed for perioperative results including OR-time, pain (VAS) and complications (Clavien-Dindo-Grading System); and for functional results (PVR, Q
resultsOf the 81 patients initially enrolled in this study, follow-up included 67 men at 1 year and 51 men at 2 years. For the 51 men included in the present analysis, the median age was 65 years, median prostate volume 37 ml (range 16-65 ml). Baseline values for IPSS and QoL were 20.51 ± 4.58, 3.96 ± 0.87. Q
conclusioniTind treatment for BPO-related LUTS showed marked and durable reduction in symptoms and improvement of functional parameters and quality of life at 24 months of follow-up. It was found that median lobe may predict failure of iTind treatment. According to the yes/no questions, ejaculatory and sexual functions do not seem to be effected following treatment, however, this finding must be supported with further studies using the accepted tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.